| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4005016 | American Journal of Ophthalmology | 2007 | 12 Pages |
Abstract
Subgroup analysis of 12-month data from the ANCHOR study showed ranibizumab to be superior to PDT in all subgroups evaluated, and was consistent with the subgroup analysis of 24-month data from the other pivotal phase 3 study of ranibizumab (MARINA) in showing that the most important predictors of VA outcomes were, in decreasing order of impact, the patient's baseline VA score, CNV lesion size, and age.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Peter K. Kaiser, David M. Brown, Kang Zhang, Henry L. Hudson, Frank G. Holz, Howard Shapiro, Susan Schneider, Nisha R. Acharya,